Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
Phase 4
Completed
- Conditions
- Epilepsy
- Registration Number
- NCT00043914
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Drug levels of lamotrigine.
- Secondary Outcome Measures
Name Time Method This study has no secondary outcome measures.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of lamotrigine in epilepsy treatment compared to valproate?
How does lamotrigine monotherapy compare to valproate in seizure control and adverse events in adults with epilepsy?
Are there specific biomarkers that predict response to lamotrigine over valproate in epilepsy patients?
What are the management strategies for adverse events during AED conversion from valproate to lamotrigine?
What are the current combination therapies involving lamotrigine for epilepsy and how do they compare to monotherapy?